1
|
Yuan B, Kikuchi H, Li J, Kawabata A, Yao K, Takagi N, Okazaki M. Cytotoxic Effects of Darinaparsin, a Novel Organic Arsenical, against Human Leukemia Cells. Int J Mol Sci 2023; 24:ijms24032282. [PMID: 36768603 PMCID: PMC9916914 DOI: 10.3390/ijms24032282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 01/10/2023] [Accepted: 01/16/2023] [Indexed: 01/26/2023] Open
Abstract
To explore the molecular mechanisms of action underlying the antileukemia activities of darinaparsin, an organic arsenical approved for the treatment of peripheral T-cell lymphoma in Japan, cytotoxicity of darinaparsin was evaluated in leukemia cell lines NB4, U-937, MOLT-4 and HL-60. Darinaparsin was a more potent cytotoxic than sodium arsenite, and induced apoptosis/necrosis in NB4 and HL-60 cells. In NB4 cells exhibiting the highest susceptibility to darinaparsin, apoptosis induction was accompanied by the activation of caspase-8/-9/-3, a substantial decrease in Bid expression, and was suppressed by Boc-D-FMK, a pancaspase inhibitor, suggesting that darinaparsin triggered a convergence of the extrinsic and intrinsic pathways of apoptosis via Bid truncation. A dramatic increase in the expression level of γH2AX, a DNA damage marker, occurred in parallel with G2/M arrest. Activation of p53 and the inhibition of cdc25C/cyclin B1/cdc2 were concomitantly observed in treated cells. Downregulation of c-Myc, along with inactivation of E2F1 associated with the activation of Rb, was observed, suggesting the critical roles of p53 and c-Myc in darinaparsin-mediated G2/M arrest. Trolox, an antioxidative reagent, suppressed the apoptosis induction but failed to correct G2/M arrest, suggesting that oxidative stress primarily contributed to apoptosis induction. Suppression of Notch1 signaling was also confirmed. Our findings provide novel insights into molecular mechanisms underlying the cytotoxicity of darinaparsin and strong rationale for its new clinical application for patients with different types of cancer.
Collapse
Affiliation(s)
- Bo Yuan
- Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Josai University, Sakado 350-0295, Japan
- Correspondence: ; Tel./Fax: +81-49-271-8026
| | - Hidetomo Kikuchi
- Laboratory of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Josai University, Sakado 350-0295, Japan
| | - Jingmei Li
- Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Josai University, Sakado 350-0295, Japan
| | - Atsushi Kawabata
- Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Josai University, Sakado 350-0295, Japan
| | - Kozo Yao
- Product Development Division, Solasia Pharma K.K., Tokyo 105-0011, Japan
| | - Norio Takagi
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Hachioji 192-0392, Japan
| | - Mari Okazaki
- Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Josai University, Sakado 350-0295, Japan
| |
Collapse
|
2
|
Yokouchi H, Mizugaki H, Ikezawa Y, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Nakamura A, M. kobayashi, Aso M, Tsukita Y, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Kitamura Y. 335P Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
3
|
Yuan B, Li J, Miyashita SI, Kikuchi H, Xuan M, Matsuzaki H, Iwata N, Kamiuchi S, Sunaga K, Sakamoto T, Hibino Y, Okazaki M. Enhanced Cytotoxic Effects of Arenite in Combination with Active Bufadienolide Compounds against Human Glioblastoma Cell Line U-87. Molecules 2022; 27:molecules27196577. [PMID: 36235115 PMCID: PMC9571627 DOI: 10.3390/molecules27196577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Revised: 09/25/2022] [Accepted: 09/29/2022] [Indexed: 11/16/2022]
Abstract
The cytotoxicity of a trivalent arsenic derivative (arsenite, AsIII) combined with arenobufagin or gamabufotalin was evaluated in human U-87 glioblastoma cells. Synergistic cytotoxicity with upregulated intracellular arsenic levels was observed, when treated with AsIII combined with arenobufagin instead of gamabufotalin. Apoptosis and the activation of caspase-9/-8/-3 were induced by AsIII and further strengthened by arenobufagin. The magnitude of increase in the activities of caspase-9/-3 was much greater than that of caspase-8, suggesting that the intrinsic pathway played a much more important role in the apoptosis. An increase in the number of necrotic cells, enhanced LDH leakage, and intensified G2/M phase arrest were observed. A remarkable increase in the expression level of γH2AX, a DNA damage marker, was induced by AsIII+arenobufagin. Concomitantly, the activation of autophagy was observed, suggesting that autophagic cell death associated with DNA damage was partially attributed to the cytotoxicity of AsIII+arenobufagin. Suppression of Notch signaling was confirmed in the combined regimen-treated cells, suggesting that inactivation of Jagged1/Notch signaling would probably contribute to the synergistic cytotoxic effect of AsIII+arenobufagin. Given that both AsIII and arenobufagin are capable of penetrating into the blood-brain barrier, our findings may provide fundamental insight into the clinical application of the combined regimen for glioblastoma.
Collapse
Affiliation(s)
- Bo Yuan
- Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
- Correspondence: ; Tel./Fax: +81-49-271-8026
| | - Jingmei Li
- Laboratory of Immunobiochemistry, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Shin-Ich Miyashita
- National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 3, 1-1-1 Umezono, Tsukuba 305-8563, Ibaraki, Japan
| | - Hidetomo Kikuchi
- Laboratory of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Meiyan Xuan
- Laboratory of Organic and Medicinal Chemistry; Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Hirokazu Matsuzaki
- Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Naohiro Iwata
- Laboratory of Immunobiochemistry, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Shinya Kamiuchi
- Laboratory of Immunobiochemistry, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Katsuyoshi Sunaga
- Laboratory of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Takeshi Sakamoto
- Laboratory of Organic and Medicinal Chemistry; Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Yasuhide Hibino
- Laboratory of Immunobiochemistry, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| | - Mari Okazaki
- Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado 350-0295, Saitama, Japan
| |
Collapse
|
4
|
Naka Y, Inami T, Takeuchi K, Kikuchi H, Goda A, Kohno T, Soejima K. Prevalence and implications of exercise pulmonary hypertension in chronic thromboembolic pulmonary disease. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Recent international statement on chronic thromboembolic pulmonary hypertension proposed the definition of chronic thromboembolic pulmonary disease (CTEPD) and advocated further research regarding its clinical characteristic, natural history, and therapeutic strategy. Exercise pulmonary hypertension (Ex-PH) has been considered a mild degree of pulmonary hypertension (PH) among patients with normal pulmonary hemodynamics at rest. However, the clinical significance of Ex-PH in CTEPD remains unknown.
Purpose
In the patients with CTEPD, we aimed to verify 1) the prevalence and clinical profiles of Ex-PH, 2) effect of BPA on pulmonary vascular response after exercise in Ex-PH, 3) long-term clinical outcomes of conservative management in non-Ex-PH.
Methods
We retrospectively reviewed 26 patients with CTEPD (median age 65 years, 38% male), who underwent cardiopulmonary exercise test with right heart catheterization (CPET-RHC). The definitions of CTEPD are the following 1) pulmonary artery occlusion due to organic thrombus confirmed by imaging studies after ≥3 months of anticoagulation, 2) mPAP<25 mmHg and PAWP≤15 mmHg at rest. PQslope was plotted using multipoint plots. Ex-PH was defined by PQ slope>3.0, and the patients were divided into Ex-PH and non-Ex PH groups. Clinical profiles and long-term outcomes were compared between two groups. The patients in Ex-PH groupunderwent CPET-RHC 6–12 months after balloon pulmonary angioplasty (BPA). In Non-Ex-PH group, serial measurements of echocardiography were performed.
Results
Overall, 5 and 21 patients were categorized as CTEPD with PH (mPAP 21–24mmHg) and without PH (mPAP≤20mmHg), and 14 and 12 were categorized Ex-PH and non-Ex-PH groups, respectively. Although all 5 patients with CTEPD with PH were classified as Ex-PH group (Figure 1), there was no significant difference in baseline hemodynamics at rest between Ex-PH and non-Ex-PH groups (mPAP: 19.5 [18.4–20.6] vs. 17.7 [16.6–18.9] mmHg, PVR: 2.2 [1.7–2.7] vs. 2.3 [1.9–2.8] wood units, P>0.05, respectively). PQ slope was significantly higher in Ex-PH group (4.6 [3.2–6.0] vs. 1.31 [0.2–2.8], p=0.002). There were no differences in respiratory function test, blood gas analysis, and 6-minute walk distance between two groups. There were no major adverse events such as all-cause mortality and hospitalization for PH in overall cohort. Among Ex-PH group, BPA decreased PQslope (4.8 [3.6–6.4] to 2.3 [1.9–3.0], p<0.05). Among no-Ex-PH group, there was no significant change in tricuspid regurgitation pressure gradient (28 [17–33] to 27 [21–36] mmHg, p>0.05) over the 997 [651–1451] days.
Conclusion
Ex-PH was common in patients with CTEPD, and there were no clinical profiles differentiating Ex-PH from non-Ex-PH, except parameters of CPET-RHC. BPA improved an abnormal pulmonary vascular response to exercise in Ex-PH. The conservative management in non-Ex-PH was feasible. Randomized clinical trials will be needed to further investigate this treatment strategy.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- Y Naka
- Kyorin University, Mitaka , Tokyo , Japan
| | - T Inami
- Kyorin University, Mitaka , Tokyo , Japan
| | - K Takeuchi
- Kyorin University, Mitaka , Tokyo , Japan
| | - H Kikuchi
- Kyorin University, Mitaka , Tokyo , Japan
| | - A Goda
- Kyorin University, Mitaka , Tokyo , Japan
| | - T Kohno
- Kyorin University, Mitaka , Tokyo , Japan
| | - K Soejima
- Kyorin University, Mitaka , Tokyo , Japan
| |
Collapse
|
5
|
Ishijima M, Nakamura T, Shimizu K, Hayashi K, Kikuchi H, Soen S, Omori G, Yamashita T, Uchio Y, Chiba J, Ideno Y, Kubota M, Kaneko H, Kurosawa H, Kaneko K. Different changes in the biomarker C-terminal telopeptides of type II collagen (CTX-II) following intra-articular injection of high molecular weight hyaluronic acid and oral non-steroidal anti-inflammatory drugs in patients with knee osteoarthritis: a multi-center randomized controlled study. Osteoarthritis Cartilage 2022; 30:852-861. [PMID: 35331859 DOI: 10.1016/j.joca.2022.03.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 02/28/2022] [Accepted: 03/14/2022] [Indexed: 02/02/2023]
Abstract
OBJECTIVES We previously reported, based on a multicenter randomized-control study, that the efficacy of intra-articular injections of hyaluronic acid (IA-HA) was not inferior to that of oral non-steroidal anti-inflammatory drugs (NSAIDs) in patients with knee osteoarthritis (OA). However, the molecular effects on the pathophysiology of knee OA remain unclear. C-terminal telopeptides of type II collagen (CTX-II) is reported to primarily originate from the interface between articular cartilage and subchondral bone, which is a site of potential remodeling in OA. We performed a predefined sub-analysis of the previous study to compare the changes of urinary CTX-II (uCTX-II) in response to IA-HA to those in response to NSAID for knee OA. DESIGN A total of 200 knee OA patients were registered from 20 hospitals and randomized to receive IA-HA (2,700 kDa HA, 5 times at 1-week intervals) or NSAID (loxoprofen sodium, 180 mg/day) for 5 weeks. The uCTX-II levels were measured before and after treatment. RESULTS The uCTX-II levels were significantly increased by IA-HA treatment (337.7 ± 193.8 to 370.7 ± 234.8 ng/μmol Cr) and were significantly reduced by NSAID treatment (423.2 ± 257.6 to 370.3 ± 250.9 ng/μmol Cr). The %changes of uCTX-II induced by IA-HA (11.6 ± 29.5%) and NSAID (-9.0 ± 26.7%) was significantly different (between-group difference: 20.6, 95% confidence intervals: 10.6 to 30.6). CONCLUSIONS While both IA-HA and NSAID improved symptoms of knee OA, uCTX-II levels were increased by IA-HA and reduced by NSAIDs treatment, suggesting these treatments may improve symptoms of knee OA through different modes of action.
Collapse
Affiliation(s)
- M Ishijima
- Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan.
| | - T Nakamura
- Department of Orthopaedic Surgery, University of Occupational and Environmental Health, Fukuoka, Japan.
| | - K Shimizu
- Department of Orthopaedic Surgery, Gifu University, School of Medicine, Gifu, Japan.
| | - K Hayashi
- Department of Laboratory Sciences, School of Health Sciences, Faculty of Medicine, Gunma University, Gunma, Japan.
| | - H Kikuchi
- Department of Orthopaedic Surgery, Kinki University Sakai Hospital, Osaka, Japan.
| | - S Soen
- Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan; Department of Laboratory Sciences, School of Health Sciences, Faculty of Medicine, Gunma University, Gunma, Japan.
| | - G Omori
- Center of Transdisciplinary Research, Institute for Research Promotion, Niigata University, Niigata, Japan.
| | - T Yamashita
- Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan.
| | - Y Uchio
- Department of Orthopaedic Surgery, Faculty of Medicine, Shimane University School of Medicine, Shimane, Japan.
| | - J Chiba
- Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan.
| | - Y Ideno
- Center of Mathematics and Data Sciences, Gunma University, Maebashi, Japan.
| | - M Kubota
- Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan.
| | - H Kaneko
- Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan.
| | - H Kurosawa
- Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan.
| | - K Kaneko
- Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan.
| | | |
Collapse
|
6
|
Nishimura Y, Kikuchi H, Kubo T, Arai R, Toguchi Y, Yuan B, Sunaga K, Cho H. Synthesis of 4,4-Disubstituted 3,4-Dihydropyrimidin-2(1H)-ones and -thiones, the Corresponding Products of Biginelli Reaction Using Ketone, and Their Antiproliferative Effect on HL-60 Cells. Chem Pharm Bull (Tokyo) 2022; 70:111-119. [PMID: 35110431 DOI: 10.1248/cpb.c21-00794] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
An efficient synthetic method for novel 4,4-disubstituted 3,4-dihydropyrimidin-2(1H)-ones 5 and -thiones 6 was developed. The cyclocondensation reaction of O-methylisourea hemisulfate salt 11 with 8 gives a tautomeric mixture of dihydropyrimidines 12 and 13 following acidic hydrolysis of the cyclized products to produce 5 in high yields. Thionation reaction of 5 at the 2-position smoothly proceeds to give 2-thioxo derivatives 6. These compounds 5 and 6, corresponding to the products of a Biginelli-type reaction using urea or thiourea, a ketone and a 1,3-dicarbonyl compound, have long been inaccessible and hitherto unavailable for medicinal chemistry. These methods are invaluable for the synthesis of 5 and 6, which have been inaccessible by conventional methods. Therefore, the synthetic methods established in this study will expand the molecular diversity of their related derivatives. These compounds were also assessed for their antiproliferative effect on a human promyelocytic leukemia cell line, HL-60. Treatment of 10 µM 6b and 6d showed high inhibitory activity similarly to 1 µM all-trans retinoic acid (ATRA), indicating that the 2-thioxo group and length of two alkyl substituents at the 4-position are strongly related to activity.
Collapse
Affiliation(s)
- Yoshio Nishimura
- School of Pharmaceutical Sciences, Ohu University.,Faculty of Pharmacy, Yasuda Women's University
| | - Hidetomo Kikuchi
- Faculty of Pharmacy and Pharmaceutical Sciences, Josai University
| | | | | | - Yuki Toguchi
- Faculty of Pharmacy and Pharmaceutical Sciences, Josai University
| | - Bo Yuan
- Faculty of Pharmacy and Pharmaceutical Sciences, Josai University
| | | | - Hidetsura Cho
- Graduate School of Pharmaceutical Sciences, Tohoku University
| |
Collapse
|
7
|
Hirose S, Rieu JP, Anjard C, Cochet-Escartin O, Kikuchi H, Funamoto K. Aerotaxis and aerokinesis of Dictyostelium discoideum under hypoxic microenvironments. Annu Int Conf IEEE Eng Med Biol Soc 2021; 2021:1187-1190. [PMID: 34891499 DOI: 10.1109/embc46164.2021.9629752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Although spatiotemporal changes of oxygen in a microenvironment are known to affect the cellular dynamics of various eukaryotes, the details are not fully understood. Here, we describe the aerotaxis and aerokinesis of Dictyostelium discoideum (Dd), which has long been employed as a model organism for eukaryotic cells. We developed a microfluidic device capable of time-lapse observation of cultured cells while controlling oxygen concentrations in microchannels. Migratory behaviors of Dd were observed and quantitatively evaluated under an oxygen concentration gradient from 0% to 21% O2, as well as in various uniform oxygen conditions. In a hypoxic region within the oxygen concentration gradient, Dd migrated toward regions of higher oxygen concentration at increased velocity, which was independent of cell density. Observed under uniform oxygen concentrations of 1%, 2%, 3%, and 21%, the migration velocity of Dd increased significantly in hypoxic environments of 2% O2 or less. Thus, Dd shows aerotaxis, directed by the oxygen concentration gradient, and simultaneously shows aerokinesis, changing the migration velocity according to the oxygen concentration itself.
Collapse
|
8
|
Kobayashi M, Mizugaki H, Ikezawa Y, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Nagano Y, Nakamura A, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Fujita Y, Oizumi S. P16.05 Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Nakamura A, Mizugaki H, Ikezawa Y, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Morita M, Aso M, Tsukita Y, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Yokouchi H. 1306P Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
10
|
Kikuchi H, Fukuda S, Koike T, Shimodaira Y, Watanabe K, Saito M, Nakagawa K, Hatta W, Masamune A, Iijima K. Association of residual gastric acid secretion with persistent symptoms in gastroesophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy. Esophagus 2021; 18:380-387. [PMID: 32737802 DOI: 10.1007/s10388-020-00765-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Accepted: 07/24/2020] [Indexed: 02/03/2023]
Abstract
BACKGROUND Although a third of gastroesophageal reflux disease (GERD) patients are refractory to proton pump inhibitor (PPI) therapy, the underlying mechanism of the refractoriness remains unclear. We compared the level of gastric acid suppression during PPI treatment between responders and non-responders by directly measuring gastric acid secretion in GERD patients taking PPIs. METHODS Seventy-five consecutive patients receiving standard-dose PPI therapy for GERD were prospectively recruited, irrespective of persistent GERD symptoms. They were asked about their GERD symptoms using a validated questionnaire, and simultaneously underwent both a routine endoscopic examination and a gastric acid secretory testing using an endoscopic gastrin test. Associations between residual gastric acid secretion during PPI treatment and persistent GERD symptoms were analyzed by a logistic regression analysis. RESULTS Overall, 26 of 75 (34.7%) patients were judged to be positive for persistent GERD symptoms. The patients with and without persistent symptoms showed similar gastric acid secretion levels (1.3 [1.3] mEq/10 min vs. 1.4 [2.0] mEq/10 min). Sufficient gastric acid suppression, defined as < 0.6, was not significantly associated with persistent GERD symptoms (odds ratio 1.1, 95% confidence interval 0.40-3.5). CONCLUSIONS This study provided solid evidence to support that the gastric acid suppression level during PPI treatment does not differ between patients with and without persistent GERD symptoms. The insignificant role of residual gastric acid in the persistent GERD symptoms suggests that the use of medications other than those that enhance gastric acid inhibitory effects would be an essential approach for the management of PPI-refractory GERD.
Collapse
Affiliation(s)
- H Kikuchi
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Sendai, 980-8574, Japan
| | - S Fukuda
- Department of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan
| | - T Koike
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Sendai, 980-8574, Japan
| | - Y Shimodaira
- Department of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan
| | - K Watanabe
- Department of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan
| | - M Saito
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Sendai, 980-8574, Japan
| | - K Nakagawa
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Sendai, 980-8574, Japan
| | - W Hatta
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Sendai, 980-8574, Japan
| | - A Masamune
- Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Sendai, 980-8574, Japan
| | - K Iijima
- Department of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan.
| |
Collapse
|
11
|
Nozaki T, Takahashi M, Ishikawa T, Haino A, Seki M, Kikuchi H, Yuan B, Nashimoto M. The heptamer sgRNA targeting the human OCT4 mRNA can upregulate the OCT4 expression. Biochem Biophys Rep 2021; 26:100918. [PMID: 33553691 PMCID: PMC7859166 DOI: 10.1016/j.bbrep.2021.100918] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 12/24/2020] [Accepted: 01/07/2021] [Indexed: 11/17/2022] Open
Abstract
TRUE gene silencing is one of the gene suppression technologies. This technology exploits the enzymatic property of the tRNA 3' processing endoribonuclease tRNase ZL, which is that it can cleave a target RNA under the direction of a small guide RNA (sgRNA). We have been working on the development of therapeutic sgRNAs for hematological malignancies. In the course of an experiment to examine the ability of the heptamer-type sgRNA H15792 targeting the OCT4 mRNA to differentiate human amnion stem cells, we observed unexpectedly that the amnion cells exhibited a morphology resembling initialized cells. Here we investigated the effect of H15792 on human HL60 leukemia cells, and found that H15792 can upregulate the OCT4 expression and the expression of alkaline phosphatase in the cells.
Collapse
Affiliation(s)
- Tadasuke Nozaki
- Department of Clinical Molecular Genetics, Faculty of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi 1432-1, Hachioji, Tokyo, 192-0392, Japan
| | - Masayuki Takahashi
- Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Higashijima 265-1, Akihaku, Niigata, Niigata, 956-8603, Japan
| | - Tatsuya Ishikawa
- Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Higashijima 265-1, Akihaku, Niigata, Niigata, 956-8603, Japan
| | - Arisa Haino
- Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Higashijima 265-1, Akihaku, Niigata, Niigata, 956-8603, Japan
| | - Mineaki Seki
- Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Higashijima 265-1, Akihaku, Niigata, Niigata, 956-8603, Japan
| | - Hidetomo Kikuchi
- Department of Clinical Molecular Genetics, Faculty of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi 1432-1, Hachioji, Tokyo, 192-0392, Japan
| | - Bo Yuan
- Department of Clinical Molecular Genetics, Faculty of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi 1432-1, Hachioji, Tokyo, 192-0392, Japan
| | - Masayuki Nashimoto
- Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Higashijima 265-1, Akihaku, Niigata, Niigata, 956-8603, Japan
| |
Collapse
|
12
|
Watanabe K, Hiramatsu Y, Honke J, Kawata S, Shirai Y, Morita Y, Kikuchi H, Takeuchi H, Yamauchi K. Dysphagia and nutritional management in esophagectomy. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Haneda R, Hiramatsu Y, Kawata S, Honke J, Watanabe K, Shirai Y, Nagafusa T, Soneda W, Hirotsu A, Matsumoto T, Morita Y, Kikuchi H, Kamiya K, Yamauchi K, Takeuchi H. Effectiveness of multidisciplinary team management with prevention of pneumonia and long-term weight loss after esophagectomy. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Hiramatsu Y, Kawata S, Watanabe K, Honke J, Shirai Y, Haneda R, Soneda W, Hirotsu A, Matsumoto T, Morita Y, Kikuchi H, Kamiya K, Yamauchi K, Takeuchi H. Clinical study on the usefulness of preoperative short-term program for nutrition and exercise before esophagectomy. Clin Nutr ESPEN 2020. [DOI: 10.1016/j.clnesp.2020.09.581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Nakata C, Goda A, Takeuchi K, Kikuchi H, Inami T, Soejima K, Satoh T. Leg raise can detect exercise-induced pulmonary arterial wedge pressure elevation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Exercise-induced elevation of pulmonary arterial wedge pressure (PAWP) may show preclinical or exercise-induced left ventricular diastolic dysfunction. Invasive hemodynamic assessment during provocative maneuvers, like exercise and volume challenge, in these patients allows greater sensitivity to diagnose or exclude HFpEF. The aim of this study was to examine how the leg raise, which is a simple way to increase preload, can detect exercise-induced PAWP elevation.
Methods
Four hundred seventy-nine patients (60±14y.o, mean pulmonary arterial pressure (PAP) 19mmHg, PAWP 8mmHg, CTEPH /IPAH/CTD-PH/SOB unknown reason: 357/56/38/28pts) with near-normal PAP and normal PAWP at rest underwent symptom-limited exercise test using supine cycle ergometer with right heart catheter. Exercise-induced elevation in PAWP of over 20mmHg was defined as exercise-induced elevation group.
Results
ΔPAWP (after leg raise - rest) in the exercise-induced elevation group was significantly higher (6.0±4.1 vs. 2.7±3.9mmHg, p<0.001, in the older (age≥60y.o) group (n=276); 3.4±3.5 vs. 1.9±3.4mmHg, p<0.001, in the younger (age<60y.o) group (n=203)) than that in the non-elevation group after legs raise for cycle ergometer exercise. The area under the ROC curve for ΔPAWP was 0.72 (95% CI: 0.65–0.78) in the older and 0.64 (95% CI: 0.53–0.75) in the younger. In the older, the cut-off value for detect exercise-induced PAWP elevation of ΔPAWP was 4mmHg, with 72% sensitivity and 58% specificity. On the other hand, in the younger, the cut-off value was 3mmHg, with 69% sensitivity and 59% specificity.
Conclusion
Leg raise can easily detect occult left ventricular diastolic dysfunction.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- C Nakata
- Kyorin University Hospital, Tokyo, Japan
| | - A Goda
- Kyorin University Hospital, Tokyo, Japan
| | - K Takeuchi
- Kyorin University Hospital, Tokyo, Japan
| | - H Kikuchi
- Kyorin University Hospital, Tokyo, Japan
| | - T Inami
- Kyorin University Hospital, Tokyo, Japan
| | - K Soejima
- Kyorin University Hospital, Tokyo, Japan
| | - T Satoh
- Kyorin University Hospital, Tokyo, Japan
| |
Collapse
|
16
|
Nakata C, Takeuchi K, Kikuchi H, Goda A, Inami T, Satoh T, Soejima K. Comparison of pulmonary vascular resistance and pulmonary artery compliance during exercise between IPAH and CTEPH with normal pulmonary artery pressure. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Pulmonary vascular resistance (PVR) and pulmonary artery compliance (PAC) are inversely related. However, the little is known about dynamics during exercise by disease difference. The aim of this study was to reveal the relationships of PVR and PAC during exercise between idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients.
Methods
Sixty-two IPAH patients (45±9 y.o) and 359 CTEPH patients (63±13 y.o) with normal mean PAP and PAWP at rest underwent symptom-limited exercise test using supine cycle ergometer with right heart catheter.
Results
There were no differences between baseline mean PAP and PAWP in 2 groups, however, cardiac output, SaO2 and SvO2 were lower in CTEPH group. Lower PAC (2.9±1.1 vs. 3.7±1.7 ml/mmHg, p<0.001) and higher PVR (2.3±1.0 vs. 1.9±1.0 wood.unit, p=0.016) were observed in CTEPH group. These trends were also seen at peak exercise. PVR-PAC relationship in CTEPH group was leftward shift compared with IPAH group (Figure 1).
Conclusion
Resting and exercise PVR and PAC in CTEPH patients were worse than those in IPAH patients who had normal PAP and PAWP at rest.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- C Nakata
- Kyorin University, Mitaka, Japan
| | | | | | - A Goda
- Kyorin University, Mitaka, Japan
| | - T Inami
- Kyorin University, Mitaka, Japan
| | - T Satoh
- Kyorin University, Mitaka, Japan
| | | |
Collapse
|
17
|
Nagamatsu Y, Inami T, Nakata C, Takeuchi K, Kikuchi H, Goda A, Soejima K, Satoh T. Usefulness of peripheral-pressure-directed balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Balloon pulmonary angioplasty (BPA) in expert center may be considered in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are technically non-operable for pulmonary endarterectomy. BPA based on objective quantitative methods has not been established. The endpoint at BPA sessions has not been clarified yet.
Objectives
The purpose of this study was to investigate the usefulness of BPA according to peripheral pressure measured by pressure wire or catheter.
Methods
This study included consecutive 143 CTEPH who underwent cardiopulmonary exercise test with right heart catheterization after BPA. All patients were divided into 2 groups such as angio-guided (n=47) group or pressure-guidedgroup (n=96). In pressure-guided group, the pulmonary arterial pressure (PAP) proximal and distal to the target lesion and the ratio of the 2 pressures were measured by the pressure wire or catheter. the endpoint was determined to when the pressure ratio of distal to proximal pressures was >0.7 to 0.8 finally. The dilation was stopped when the distal mean PAP after each dilation reached 35 mm Hg and when the baseline mean PAP was >35 mm Hg. Changes of hemodynamic parameters such as PAP and pulmonary vascular resistance (PVR) from baseline, and mean PAP and PVR at peak oxygen consumption, and pulmonary arterial pressure – cardiac output (PA-CO) slope were compared between two groups. All data except changes of hemodynamics from baseline were expressed by median [25th percentile-75th percentile]. Changes of hemodynamics from baseline were expressed by average [95% confidence interval]
Results
The median age and male were 66 [56–72] years old and 35. There were no significant differences in number of sessions and dilated vessels between two groups (Angio-guided group vs. Pressure-guided group: 4 [3–6] vs. 4 [3–5], P>0.05; 19 [12–22] vs. 17 [13–22], P>0.05). Changes of PAP and PVR from baseline in pressure-guided group was significantly higher than in angio-guided groups (Angio-guided group vs. Pressure-guided group; ΔPAP: −19 [−20 to −17] vs. −20 [−21 to −20], P>0.05; ΔPVR: −6.0 [−6.3 to −5.7] vs. −6.6 [−6.8 to −6.3], P<0.01). Mean PAP and PVR at peak oxygen consumption (VO2) and PA-CO slope in pressure-guided group were significantly lower than in angio-guided group (Angio-guided group vs. Pressure-guided group; PAP at VO2: 43 [36–50] vs. 39 [34–43], P<0.05; PVR at VO2: 2.7 [1.9–4.5] vs. 2.2 [1.6–2.9], P<0.01; PA-CO slope: 3.8 [2.1–5.2] vs. 2.9 [1.9–4.0], P<0.05).
Conclusions
Peripheral-pressure-directed BPA can improve hemodynamics at rest and exercise more effectively.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- Y Nagamatsu
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - T Inami
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - C Nakata
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - K Takeuchi
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - H Kikuchi
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - A Goda
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - K Soejima
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| | - T Satoh
- Kyorin University School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan
| |
Collapse
|
18
|
Kikuchi H, Toyoda N, Ezawa S, Yoshida S, Hibino Y, Sunaga K. Effects of hot‑water extracts from 26 herbs on α‑glucosidase activity. Mol Med Rep 2020; 22:3525-3532. [PMID: 32945423 DOI: 10.3892/mmr.2020.11397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2019] [Accepted: 06/04/2020] [Indexed: 11/05/2022] Open
Abstract
α‑glucosidase is a key enzyme that plays a role in glucose absorption in the gastrointestinal tract, and the inhibition of its activity induces the prevention of postprandial hyperglycemia. Several α‑glucosidase inhibitors have been used as medicines for type 2 diabetes, but a similar effect is observed in natural resources, including traditional herbs and their phytochemicals. To identify the presence of the α‑glucosidase inhibitory activity in herbs, in which various functional effects have been known to occur, the present study investigated the effects of hot‑water extracts of 26 types of herbs on α‑glucosidase activity in an in vitro assay. The results indicated significant increases in the inhibition of α‑glucosidase activity in 1,000 µg/ml olive (P<0.01), white willow (P<0.01) and red rooibos hot‑water extracts. Furthermore, ≥50% inhibition of α‑glucosidase activity was determined to be significant in 1,000 µg/ml coltsfoot, green tea and bearberry hot‑water extracts. In addition, the effects of bearberry, green tea and coltsfoot hot‑water extracts on α‑glucosidase activity in vivo were evaluated according to the blood glucose levels (BGLs) in maltose and glucose load model rats. It was indicated that the administration of these three herb extracts significantly reduced the increasing BGLs after maltose loading until 0.5 h compared with the control group. However, only coltsfoot extract significantly reduced the increasing BGLs after glucose loading until 0.5 h compared with the control group. Thus, the present results may facilitate the understanding of a novel functionality in traditional herbs, which could be useful for the prevention of disease onset and progression, such as in hyperglycemia and type 2 diabetes.
Collapse
Affiliation(s)
- Hidetomo Kikuchi
- Laboratory of Pharmacotherapy, Clinical Dietetics and Human Nutrition, Master's Program, Josai University Graduate School of Pharmaceutical Sciences, Sakado, Saitama 350‑0295, Japan
| | - Nana Toyoda
- Laboratory of Pharmacotherapy, Clinical Dietetics and Human Nutrition, Master's Program, Josai University Graduate School of Pharmaceutical Sciences, Sakado, Saitama 350‑0295, Japan
| | - Satoko Ezawa
- Laboratory of Pharmacotherapy, Clinical Dietetics and Human Nutrition, Master's Program, Josai University Graduate School of Pharmaceutical Sciences, Sakado, Saitama 350‑0295, Japan
| | - Shiori Yoshida
- Laboratory of Pharmacotherapy, Clinical Dietetics and Human Nutrition, Master's Program, Josai University Graduate School of Pharmaceutical Sciences, Sakado, Saitama 350‑0295, Japan
| | - Yasuhide Hibino
- Laboratory of Pharmacotherapy, Clinical Dietetics and Human Nutrition, Master's Program, Josai University Graduate School of Pharmaceutical Sciences, Sakado, Saitama 350‑0295, Japan
| | - Katsuyoshi Sunaga
- SunagaLaboratory of Pharmacotherapy, Clinical Dietetics and Human Nutrition, Master's Program, Josai University Graduate School of Pharmaceutical Sciences, Sakado, Saitama 350‑0295, Japan
| |
Collapse
|
19
|
Yu B, Yuan B, Li J, Kiyomi A, Kikuchi H, Hayashi H, Hu X, Okazaki M, Sugiura M, Hirano T, Fan Y, Pei X, Takagi N. JNK and Autophagy Independently Contributed to Cytotoxicity of Arsenite combined With Tetrandrine via Modulating Cell Cycle Progression in Human Breast Cancer Cells. Front Pharmacol 2020; 11:1087. [PMID: 32765280 PMCID: PMC7379898 DOI: 10.3389/fphar.2020.01087] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 07/03/2020] [Indexed: 12/12/2022] Open
Abstract
Novel therapeutic strategies for breast cancer are urgently needed due to the sustained development of drug resistance and tumor recurrence. Trivalent arsenic derivative (arsenite, AsIII) has been reported to induce cytotoxicity in breast cancer cells. We recently demonstrated that AsIII plus tetrandrine (Tetra), a Chinese plant-derived alkaloid, exerted potent antitumor activity against human breast cancer cells, however, the underlying mechanisms for their action have not been well defined. In order to provide fundamental insights for understanding the action of AsIII plus Tetra, the effects of the combined regimen on two breast cancer cell lines T47D and MDA-MB-231 were evaluated. Compared to T47D cells, MDA-MB-231 cells were much more susceptible to the synergistic cytotoxic effects of AsIII and Tetra. Besides the induction of apoptotic/necrotic cell death, S-phase arrest and autophagic cell death were also observed in MDA-MB-231 cells. Exposure of MDA-MB-231 cells to AsIII and Tetra caused the activation of MAPKs. Cytotoxicity of the combined regimen in MDA-MB-231 cell was significantly abrogated by SP600125, a potent c-Jun N-terminal kinase (JNK) inhibitor. However, similar abrogation was not caused by p38 and ERK inhibitors. The addition of either autophagy inhibitors (3-methyladenine or wortmannin) or SP600125 corrected the combined regimen-triggered S-phase arrest, whereas had little effect on the apoptosis/necrosis induction in the cells. Surprisingly, SP600125NC, a negative control for SP600125, significantly strengthened S-phase arrest and the cytotoxicity induced by the combined regimen. The addition of SP600125 did not alter autophagy induction. In conclusion, the cytotoxicity of AsIII combined with Tetra was attributed to the induction of S-phase arrest, apoptotic/necrotic and autophagic cell death. The enhanced cytotoxicity of the two drugs by SP600125NC might be explained by its capability to strengthen S-phase arrest. Our results suggested that JNK and autophagy independently contributed to the cytotoxicity via modulating cell cycle progression. The study further provides fundamental insights for the development of AsIII in combination with Tetra for patients with different types of breast cancer.
Collapse
Affiliation(s)
- Bowen Yu
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan.,Galactophore Department, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
| | - Bo Yuan
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan.,Laboratory of Pharmacology, School of Pharmacy, Josai University, Saitama, Japan
| | - JingZhe Li
- Beijing Key Laboratory of Research of Chinese Medicine on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
| | - Anna Kiyomi
- Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan
| | - Hidetomo Kikuchi
- Laboratory of Pharmacotherapy, Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Saitama, Japan
| | - Hideki Hayashi
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan
| | - Xiaomei Hu
- Hematology Department, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Mari Okazaki
- Laboratory of Pharmacology, School of Pharmacy, Josai University, Saitama, Japan
| | - Munetoshi Sugiura
- Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan
| | - Toshihiko Hirano
- Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan
| | - Yingyi Fan
- Galactophore Department, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
| | - Xiaohua Pei
- Galactophore Department, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
| | - Norio Takagi
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, Tokyo, Japan
| |
Collapse
|
20
|
Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Matsumoto R, Osawa T, Maruyama S, IshizakiIshizaki J, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Murai S, Shinohara N. Erratum to: Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma. Jpn J Clin Oncol 2020; 50:726. [PMID: 32382760 PMCID: PMC7284546 DOI: 10.1093/jjco/hyz196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Revised: 05/15/2019] [Accepted: 05/21/2019] [Indexed: 11/21/2022] Open
Affiliation(s)
- T Abe
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - K Minami
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - T Harabayashi
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - A Sazawa
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - H Chiba
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - H Kikuchi
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - H Miyata
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - R Matsumoto
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - T Osawa
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - S Maruyama
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | | | - T Mochizuki
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - S Chiba
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - T Akino
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - M Murakumo
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - N Miyajima
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - K Tsuchiya
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - S Murai
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - N Shinohara
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| |
Collapse
|
21
|
Hirohata S, Kikuchi H, Sawada T, Kuwana M, Kirino Y, Takeno M, Ishigatsubo Y. AB0482 INFLUENCES OF TIME OF INTRODUCTION OF INFLIXIMAB ON THE FUNCTIONAL DISABILITY AND JOB STATUS OF PATIENTS WITH CHRONIC PROGRESSIVE NEURO-BEHCET’S DISEASE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Chronic progressive neuro-Behcet’s disease (CPNBD) is characterized by progressive neurobehaviour changes leading to disability and death. It has been appreciated that methotrexate is effective for CPNBD. Notably, recent studies have demonstrated that infliximab is effective for patients with CPNBD who had inadequate responses to methotrexate. However, the appropriate timing for introduction of infliximab remains unclear.Objectives:The current studies examined the effects of intervals before introduction of infliximab on the functional disability and job status of patients with CPNBD.Methods:Eleven patients (8 males, 3 females, ages 35.2±9.3 [mean±SD]), who met the international classification criteria for BD with CPNBD and received infliximab, were retrospectively followed up. The functional disability of the patients was evaluated by Steinbrocker functional classification as is used in rheumatoid arthritis. Correlation between the patients’ functional outcome and the intervals before the introduction of infliximab was analyzed by Spearman’s rank correlation test.Results:All the 11 patients had received methotrexate prior to infliximab. The intervals from the onset to the introduction of infliximab and the follow-up periods were 26.6±35.1 months and 65.2±43.6 months [mean±SD], respectively. Among the 11 patients, 9 patients did not show progression after the introduction of infliximab, whereas 2 patients still progressed and lost job. In the latter 2 patients, infliximab had been discontinued before the final follow-up. No patients improved from the functional disability or gained job even after infliximab treatment. The functional disability grades of the patients after the introduction of infliximab were significantly correlated with the intervals from the onset of CPNBD to the introduction of infliximab (r=0.6177, p=0.0476).Conclusion:The results indicate that the delay of the introduction of infliximab leads to the irreversible functional disability and job loss of the patients with CPNBD. Thus, it is recommended that infliximab should be administered as soon as possible for the patients with CPNBD with inadequate response to methotrexate.References:[1]Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive Neuro-Behcet’s syndrome.J Neurol Sci2008; 272: 99-105Disclosure of Interests: :Shunsei Hirohata Speakers bureau: Tanabe Mitsubishi, Hirotoshi Kikuchi Speakers bureau: Tanabe Mitsubishi, Tetsuji Sawada: None declared, Masataka Kuwana Grant/research support from: Acetelion, Consultant of: Acetelion, Bayer, Chugai, Corbus Pharmaceuticals, CSL Behring and Reata Pharmaceuticals. He was a member of the SENSCIS trial Steering Committee (Boehringer Ingelheim), Yohei Kirino: None declared, Mitsuhiro Takeno Speakers bureau: Esai, Tanabe-Mitsubishi – speaker; Celgene Corporation – advisory board, Yoshiaki Ishigatsubo: None declared
Collapse
|
22
|
Morota T, Sugita S, Cho Y, Kanamaru M, Tatsumi E, Sakatani N, Honda R, Hirata N, Kikuchi H, Yamada M, Yokota Y, Kameda S, Matsuoka M, Sawada H, Honda C, Kouyama T, Ogawa K, Suzuki H, Yoshioka K, Hayakawa M, Hirata N, Hirabayashi M, Miyamoto H, Michikami T, Hiroi T, Hemmi R, Barnouin OS, Ernst CM, Kitazato K, Nakamura T, Riu L, Senshu H, Kobayashi H, Sasaki S, Komatsu G, Tanabe N, Fujii Y, Irie T, Suemitsu M, Takaki N, Sugimoto C, Yumoto K, Ishida M, Kato H, Moroi K, Domingue D, Michel P, Pilorget C, Iwata T, Abe M, Ohtake M, Nakauchi Y, Tsumura K, Yabuta H, Ishihara Y, Noguchi R, Matsumoto K, Miura A, Namiki N, Tachibana S, Arakawa M, Ikeda H, Wada K, Mizuno T, Hirose C, Hosoda S, Mori O, Shimada T, Soldini S, Tsukizaki R, Yano H, Ozaki M, Takeuchi H, Yamamoto Y, Okada T, Shimaki Y, Shirai K, Iijima Y, Noda H, Kikuchi S, Yamaguchi T, Ogawa N, Ono G, Mimasu Y, Yoshikawa K, Takahashi T, Takei Y, Fujii A, Nakazawa S, Terui F, Tanaka S, Yoshikawa M, Saiki T, Watanabe S, Tsuda Y. Sample collection from asteroid (162173) Ryugu by Hayabusa2: Implications for surface evolution. Science 2020; 368:654-659. [DOI: 10.1126/science.aaz6306] [Citation(s) in RCA: 104] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Accepted: 04/02/2020] [Indexed: 11/02/2022]
Affiliation(s)
- T. Morota
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
- Departments of Earth and Environmental Sciences and Physics, Nagoya University, Nagoya 464-8601, Japan
| | - S. Sugita
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - Y. Cho
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - M. Kanamaru
- Department of Earth and Space Science, Osaka University, Toyonaka 560-0043, Japan
| | - E. Tatsumi
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
- Departamento de Astrofísica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain
- Instituto de Astrofísica de Canarias, 38205 La Laguna, Tenerife, Spain
| | - N. Sakatani
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - R. Honda
- Department of Information Science, Kochi University, Kochi 780-8520, Japan
| | - N. Hirata
- Department of Planetology, Kobe University, Kobe 657-8501, Japan
| | - H. Kikuchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M. Yamada
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - Y. Yokota
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Department of Information Science, Kochi University, Kochi 780-8520, Japan
| | - S. Kameda
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - M. Matsuoka
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H. Sawada
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - C. Honda
- School of Computer Science and Engineering, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - T. Kouyama
- National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064 Japan
| | - K. Ogawa
- Department of Planetology, Kobe University, Kobe 657-8501, Japan
- JAXA Space Exploration Center, Japan Aerospace Exploration Agency, Sagamihara 252-5210, Japan
| | - H. Suzuki
- Department of Physics, Meiji University, Kawasaki 214-8571, Japan
| | - K. Yoshioka
- Department of Complexity Science and Engineering, The University of Tokyo, Kashiwa 277-8561, Japan
| | - M. Hayakawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N. Hirata
- School of Computer Science and Engineering, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - M. Hirabayashi
- Department of Aerospace Engineering, Auburn University, Auburn, AL 36849, USA
| | - H. Miyamoto
- Department of Systems Innovation, The University of Tokyo, Tokyo 113-8656, Japan
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - T. Michikami
- Faculty of Engineering, Kindai University, Higashi-Hiroshima 739-2116, Japan
| | - T. Hiroi
- Department of Earth, Environmental and Planetary Sciences, Brown University, Providence, RI 02912, USA
| | - R. Hemmi
- The University Museum, The University of Tokyo, Tokyo 113-0033, Japan
| | - O. S. Barnouin
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - C. M. Ernst
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - K. Kitazato
- School of Computer Science and Engineering, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - T. Nakamura
- Department of Earth Science, Tohoku University, Sendai 980-8578, Japan
| | - L. Riu
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H. Senshu
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - H. Kobayashi
- Departments of Earth and Environmental Sciences and Physics, Nagoya University, Nagoya 464-8601, Japan
| | - S. Sasaki
- Department of Earth and Space Science, Osaka University, Toyonaka 560-0043, Japan
| | - G. Komatsu
- International Research School of Planetary Sciences, Università d’Annunzio, 65127 Pescara, Italy
| | - N. Tanabe
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - Y. Fujii
- Department of Information Science, Kochi University, Kochi 780-8520, Japan
| | - T. Irie
- Departments of Earth and Environmental Sciences and Physics, Nagoya University, Nagoya 464-8601, Japan
| | - M. Suemitsu
- Departments of Earth and Environmental Sciences and Physics, Nagoya University, Nagoya 464-8601, Japan
| | - N. Takaki
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - C. Sugimoto
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - K. Yumoto
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - M. Ishida
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - H. Kato
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - K. Moroi
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - D. Domingue
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - P. Michel
- Université Côte d’Azur, Observatoire de la Côte d’Azur, Centre National de le Recherche Scientifique, Laboratoire Lagrange, 06304 Nice, France
| | - C. Pilorget
- Institut d’Astrophysique Spatiale, Université Paris-Sud, 91405 Orsay, France
| | - T. Iwata
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - M. Abe
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - M. Ohtake
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- School of Computer Science and Engineering, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y. Nakauchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K. Tsumura
- Department of Natural Science, Faculty of Science and Engineering, Tokyo City University, Tokyo 158-8557, Japan
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai 980-8578, Japan
| | - H. Yabuta
- Department of Earth and Planetary Systems Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - Y. Ishihara
- National Institute for Environmental Studies, Tsukuba 305-8506, Japan
| | - R. Noguchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K. Matsumoto
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - A. Miura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - N. Namiki
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S. Tachibana
- Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M. Arakawa
- Department of Planetology, Kobe University, Kobe 657-8501, Japan
| | - H. Ikeda
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - K. Wada
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - T. Mizuno
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - C. Hirose
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - S. Hosoda
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - O. Mori
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T. Shimada
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S. Soldini
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Department of Mechanical, Materials and Aerospace Engineering, University of Liverpool, Liverpool L69 3BX, UK
| | - R. Tsukizaki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H. Yano
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - M. Ozaki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - H. Takeuchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - Y. Yamamoto
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - T. Okada
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Department of Chemistry, The University of Tokyo, Tokyo 113-0033, Japan
| | - Y. Shimaki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K. Shirai
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y. Iijima
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H. Noda
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S. Kikuchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T. Yamaguchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N. Ogawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - G. Ono
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - Y. Mimasu
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K. Yoshikawa
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - T. Takahashi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y. Takei
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - A. Fujii
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S. Nakazawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - F. Terui
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S. Tanaka
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - M. Yoshikawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - T. Saiki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S. Watanabe
- Departments of Earth and Environmental Sciences and Physics, Nagoya University, Nagoya 464-8601, Japan
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y. Tsuda
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
- Departments of Space and Astronautical Science and Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| |
Collapse
|
23
|
Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Matsumoto R, Osawa T, Maruyama S, Ishizaki J, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Murai S, Shinohara N. Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma. Jpn J Clin Oncol 2020; 49:965-971. [PMID: 31187865 PMCID: PMC6886465 DOI: 10.1093/jjco/hyz084] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Revised: 05/15/2019] [Accepted: 05/21/2019] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE Aiming to achieve long-term disease control, maintenance systemic chemotherapy (MSC) with a 1-3-month drug-free interval is continued in selected patients. We report our experience of MSC for metastatic urothelial carcinoma (UC). METHODS Of 228 metastatic UC patients treated with systemic chemotherapy, 40 (17.5%, 40/228) had continuously undergone MSC. Data on the regimen, cycle number, and reason for the discontinuation of MSC were also collected. We analyzed OS from the initiation of MSC until death or the last follow-up, using the log-rank test to assess the significance of differences. RESULTS The median number of cycles of chemotherapy was 6, and the responses were CR in 6, PR in 20, SD in 13, and PD in 1 before MSC. Gemcitabine plus CDDP or carboplatin was mainly performed as MSC (70%, 28/40). MSC was repeated quarterly in 30 (75%, 30/40), every two months in 8 (20%, 8/40), and with other intervals in 2 (5%, 2/40). Overall, a median of 3.5 cycles (range: 1-29) of MSC was performed. The reason for the discontinuation of MSC was PD in 24 (60%, 24/40), favorable disease control in 9 (22.5%, 9/40), and myelosuppression in 3 (7.5%, 3/40), and for other reasons in 2 (5%, 2/40). MSC was ongoing in 2 (5%, 2/40). The median OS was 27 months from the initiation of MSC. PS0 (P = 0.0169), the absence of lung metastasis (P = 0.0387), and resection of the primary site (P = 0.0495) were associated with long-term survival after MSC. CONCLUSIONS In selected patients, long-term systemic chemotherapy could be performed with a drug-free interval. Our maintenance strategy with cytotoxic drugs may become one of the treatment options for long-term disease control.
Collapse
Affiliation(s)
- T Abe
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - K Minami
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - T Harabayashi
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - A Sazawa
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - H Chiba
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - H Kikuchi
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - H Miyata
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - R Matsumoto
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - T Osawa
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - S Maruyama
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - J Ishizaki
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - T Mochizuki
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - S Chiba
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - T Akino
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - M Murakumo
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - N Miyajima
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - K Tsuchiya
- Hokkaido Urothelial Cancer Research Group, Sapporo, Japan
| | - S Murai
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| | - N Shinohara
- Department of Urology, Hokkaido University Hospital, Sapporo, Japan
| |
Collapse
|
24
|
Yu B, Yuan B, Kiyomi A, Kikuchi H, Hayashi H, Hu X, Okazaki M, Sugiura M, Hirano T, Pei X, Takagi N. Differentiation induction of human breast cancer cells by arsenite in combination with tetrandrine. Am J Transl Res 2019; 11:7310-7323. [PMID: 31934280 PMCID: PMC6943472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2019] [Accepted: 10/25/2019] [Indexed: 06/10/2023]
Abstract
BACKGROUND To provide novel insight into the development of new therapeutic strategies to combat breast cancer, differentiation-inducing activity of clinically achievable concentrations of arsenite (AsIII) and tetrandrine (Tetra) was investigated in breast cancer cell lines MDA-MB-231 and MCF-7. METHODS Differentiation induction of cancer cells was analyzed by flow cytometer. Alterations of genes related to differentiation, and proliferation of human normal peripheral blood mononuclear cells (PBMCs) were analyzed using western blotting and cell viability assay, respectively. RESULTS Exposure to Tetra alone or in combination with AsIII induced differentiation of both cells characterized by upregulation of ICAM-1, downregulation of Her2/neu. In comparison with MCF-7, the combination of lower concentrations of AsIII and Tetra induced differentiation of MDA-MB-231, indicating that MDA-MB-231 cells were highly susceptible to differentiation. The differentiation occurred in parallel with activation of Erk signaling pathway, and was abolished by PD98059, a potent Erk inhibitor. Consistent with in vitro experimental results, the upregulation of ICAM-1 and the activation of Erk signaling pathway were also observed in MDA-MB-231 breast tumors in xenograft mouse obtained from our previous study. No obvious proliferation inhibition of PBMCs was observed following the exposure to AsIII combined with Tetra at the concentrations capable of inducing differentiation of MDA-MB-231 cells. CONCLUSION The Erk signaling pathway may be crucially involved in the differentiation induction of breast cancer cells in vitro and in vivo. Collectively, our results suggest that the combination can probably serve as promising candidates for the development of novel therapeutic approaches for different types of breast cancer.
Collapse
Affiliation(s)
- Bowen Yu
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
- Beijing University of Chinese Medicine Third Affiliated HospitalBeijing 100029, P. R. China
| | - Bo Yuan
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
- Laboratory of Pharmacology, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Anna Kiyomi
- Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
| | - Hidetomo Kikuchi
- Laboratory of Pharmacotherapy, Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Hideki Hayashi
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
| | - Xiaomei Hu
- Xiyuan Hospital, China Academy of Chinese Medical SciencesBeijing 100091, P. R. China
| | - Mari Okazaki
- Laboratory of Pharmacology, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Munetoshi Sugiura
- Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
| | - Toshihiko Hirano
- Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
| | - Xiaohua Pei
- Beijing University of Chinese Medicine Third Affiliated HospitalBeijing 100029, P. R. China
| | - Norio Takagi
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
| |
Collapse
|
25
|
Kikuchi H, Yuan B, Hu X, Okazaki M. Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents. Am J Cancer Res 2019; 9:1517-1535. [PMID: 31497340 PMCID: PMC6726994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Accepted: 06/11/2019] [Indexed: 06/10/2023] Open
Abstract
Cancer is a diverse class of diseases characterized by uncontrolled cell growth with the potential to invade and spread to other parts of the body, and continues to be one of the leading causes of death worldwide. Conventional cancer treatment modalities include antitumor drugs, surgical resection, locally targeted therapies such as radiation therapy. Along with improved understanding of the molecular pathogenesis of various cancers, generation and the use of smart targeted anti-cancer drugs have been challenged. The need for novel therapeutic strategies remains paramount given the sustained development of drug resistance, tumor recurrence, and metastasis. Development of new strategies aimed at improving chemotherapy sensitivity and minimizing the adverse side effects is thus essential for obtaining satisfied therapeutic outcomes for patients and enhancing their quality of life. Emerging evidence has reported that many cancer patients use either herbs employed in complementary therapies or dietary agents that influence cellular signaling worldwide. Numerous components of edible plants, collectively termed phytochemicals that have beneficial effects for health, are being reported increasingly in the scientific literature. Of those, flavonoids have attracted much attention by virtue of its wide variety of biological functions including antioxidant, anti-inflammatory, and anticancer activity. In this review, we highlight the molecular mechanisms underlying its multiple pharmacological effects, especially focusing on cancer chemoprevention. We further discuss possible strategies to develop anticancer therapy by combining flavonoids nutraceuticals and conventional chemotherapeutic agents. We also highlight numerous pharmacokinetic challenges such as bioavailability, drug-drug interactions, which are still fundamental questions concerning its future clinical application.
Collapse
Affiliation(s)
- Hidetomo Kikuchi
- Laboratory of Pharmacotherapy, Department of Clinical Dietetics and Human Nutrition, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Bo Yuan
- Laboratory of Pharmacology, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| | - Xiaomei Hu
- Xiyuan Hospital, China Academy of Chinese Medical SciencesBeijing 100091, People’s Republic of China
| | - Mari Okazaki
- Laboratory of Pharmacology, School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
| |
Collapse
|
26
|
Watanabe S, Hirabayashi M, Hirata N, Hirata N, Noguchi R, Shimaki Y, Ikeda H, Tatsumi E, Yoshikawa M, Kikuchi S, Yabuta H, Nakamura T, Tachibana S, Ishihara Y, Morota T, Kitazato K, Sakatani N, Matsumoto K, Wada K, Senshu H, Honda C, Michikami T, Takeuchi H, Kouyama T, Honda R, Kameda S, Fuse T, Miyamoto H, Komatsu G, Sugita S, Okada T, Namiki N, Arakawa M, Ishiguro M, Abe M, Gaskell R, Palmer E, Barnouin OS, Michel P, French AS, McMahon JW, Scheeres DJ, Abell PA, Yamamoto Y, Tanaka S, Shirai K, Matsuoka M, Yamada M, Yokota Y, Suzuki H, Yoshioka K, Cho Y, Tanaka S, Nishikawa N, Sugiyama T, Kikuchi H, Hemmi R, Yamaguchi T, Ogawa N, Ono G, Mimasu Y, Yoshikawa K, Takahashi T, Takei Y, Fujii A, Hirose C, Iwata T, Hayakawa M, Hosoda S, Mori O, Sawada H, Shimada T, Soldini S, Yano H, Tsukizaki R, Ozaki M, Iijima Y, Ogawa K, Fujimoto M, Ho TM, Moussi A, Jaumann R, Bibring JP, Krause C, Terui F, Saiki T, Nakazawa S, Tsuda Y. Hayabusa2 arrives at the carbonaceous asteroid 162173 Ryugu-A spinning top-shaped rubble pile. Science 2019; 364:268-272. [PMID: 30890588 DOI: 10.1126/science.aav8032] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Accepted: 03/07/2019] [Indexed: 11/02/2022]
Abstract
The Hayabusa2 spacecraft arrived at the near-Earth carbonaceous asteroid 162173 Ryugu in 2018. We present Hayabusa2 observations of Ryugu's shape, mass, and geomorphology. Ryugu has an oblate "spinning top" shape, with a prominent circular equatorial ridge. Its bulk density, 1.19 ± 0.02 grams per cubic centimeter, indicates a high-porosity (>50%) interior. Large surface boulders suggest a rubble-pile structure. Surface slope analysis shows Ryugu's shape may have been produced from having once spun at twice the current rate. Coupled with the observed global material homogeneity, this suggests that Ryugu was reshaped by centrifugally induced deformation during a period of rapid rotation. From these remote-sensing investigations, we identified a suitable sample collection site on the equatorial ridge.
Collapse
Affiliation(s)
- S Watanabe
- Nagoya University, Nagoya 464-8601, Japan. .,Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | | | - N Hirata
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Na Hirata
- Kobe University, Kobe 657-8501, Japan
| | - R Noguchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Shimaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Ikeda
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - E Tatsumi
- University of Tokyo, Tokyo 113-0033, Japan
| | - M Yoshikawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - S Kikuchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Yabuta
- Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - T Nakamura
- Tohoku University, Sendai 980-8578, Japan
| | - S Tachibana
- University of Tokyo, Tokyo 113-0033, Japan.,Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Ishihara
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Morota
- Nagoya University, Nagoya 464-8601, Japan
| | - K Kitazato
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - N Sakatani
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Matsumoto
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - K Wada
- Chiba Institute of Technology, Narashino 275-0016, Japan
| | - H Senshu
- Chiba Institute of Technology, Narashino 275-0016, Japan
| | - C Honda
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - T Michikami
- Kindai University, Higashi-Hiroshima 739-2116, Japan
| | - H Takeuchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - T Kouyama
- National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064 Japan
| | - R Honda
- Kochi University, Kochi 780-8520, Japan
| | - S Kameda
- Rikkyo University, Tokyo 171-8501, Japan
| | - T Fuse
- National Institute of Information and Communications Technology, Kashima 314-8501, Japan
| | - H Miyamoto
- University of Tokyo, Tokyo 113-0033, Japan
| | - G Komatsu
- Università d'Annunzio, 65127 Pescara, Italy.,Chiba Institute of Technology, Narashino 275-0016, Japan
| | - S Sugita
- University of Tokyo, Tokyo 113-0033, Japan
| | - T Okada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,University of Tokyo, Tokyo 113-0033, Japan
| | - N Namiki
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - M Arakawa
- Kobe University, Kobe 657-8501, Japan
| | - M Ishiguro
- Seoul National University, Seoul 08826, Korea
| | - M Abe
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - R Gaskell
- Planetary Science Institute, Tucson, AZ 85710, USA
| | - E Palmer
- Planetary Science Institute, Tucson, AZ 85710, USA
| | - O S Barnouin
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - P Michel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre National de la Recherche Scientifique (CNRS), Laboratoire Lagrange, 06304 Nice, France
| | - A S French
- University of Colorado, Boulder, CO 80309, USA
| | - J W McMahon
- University of Colorado, Boulder, CO 80309, USA
| | | | - P A Abell
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - Y Yamamoto
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - S Tanaka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - K Shirai
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Matsuoka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Yamada
- Chiba Institute of Technology, Narashino 275-0016, Japan
| | - Y Yokota
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Kochi University, Kochi 780-8520, Japan
| | - H Suzuki
- Meiji University, Kawasaki 214-8571, Japan
| | - K Yoshioka
- University of Tokyo, Tokyo 113-0033, Japan
| | - Y Cho
- University of Tokyo, Tokyo 113-0033, Japan
| | - S Tanaka
- Kobe University, Kobe 657-8501, Japan
| | | | - T Sugiyama
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - H Kikuchi
- University of Tokyo, Tokyo 113-0033, Japan
| | - R Hemmi
- University of Tokyo, Tokyo 113-0033, Japan
| | - T Yamaguchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N Ogawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - G Ono
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - Y Mimasu
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Yoshikawa
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - T Takahashi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Takei
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - A Fujii
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - C Hirose
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - T Iwata
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - M Hayakawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Hosoda
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - O Mori
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Sawada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Shimada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Soldini
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Yano
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - R Tsukizaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Ozaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - Y Iijima
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Ogawa
- Kobe University, Kobe 657-8501, Japan
| | - M Fujimoto
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T-M Ho
- DLR (German Aerospace Center), Institute of Space Systems, 28359 Bremen, Germany
| | - A Moussi
- Centre National d'Etudes Spatiales (CNES), 31401 Toulouse, France
| | - R Jaumann
- DLR, Institute of Planetary Research, 12489 Berlin-Adlershof, Germany
| | - J-P Bibring
- Institute d'Astrophysique Spatiale, 91405 Orsay, France
| | - C Krause
- DLR, Microgravity User Support Center, 51147 Cologne, Germany
| | - F Terui
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Saiki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Nakazawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Tsuda
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| |
Collapse
|
27
|
Sugita S, Honda R, Morota T, Kameda S, Sawada H, Tatsumi E, Yamada M, Honda C, Yokota Y, Kouyama T, Sakatani N, Ogawa K, Suzuki H, Okada T, Namiki N, Tanaka S, Iijima Y, Yoshioka K, Hayakawa M, Cho Y, Matsuoka M, Hirata N, Hirata N, Miyamoto H, Domingue D, Hirabayashi M, Nakamura T, Hiroi T, Michikami T, Michel P, Ballouz RL, Barnouin OS, Ernst CM, Schröder SE, Kikuchi H, Hemmi R, Komatsu G, Fukuhara T, Taguchi M, Arai T, Senshu H, Demura H, Ogawa Y, Shimaki Y, Sekiguchi T, Müller TG, Hagermann A, Mizuno T, Noda H, Matsumoto K, Yamada R, Ishihara Y, Ikeda H, Araki H, Yamamoto K, Abe S, Yoshida F, Higuchi A, Sasaki S, Oshigami S, Tsuruta S, Asari K, Tazawa S, Shizugami M, Kimura J, Otsubo T, Yabuta H, Hasegawa S, Ishiguro M, Tachibana S, Palmer E, Gaskell R, Le Corre L, Jaumann R, Otto K, Schmitz N, Abell PA, Barucci MA, Zolensky ME, Vilas F, Thuillet F, Sugimoto C, Takaki N, Suzuki Y, Kamiyoshihara H, Okada M, Nagata K, Fujimoto M, Yoshikawa M, Yamamoto Y, Shirai K, Noguchi R, Ogawa N, Terui F, Kikuchi S, Yamaguchi T, Oki Y, Takao Y, Takeuchi H, Ono G, Mimasu Y, Yoshikawa K, Takahashi T, Takei Y, Fujii A, Hirose C, Nakazawa S, Hosoda S, Mori O, Shimada T, Soldini S, Iwata T, Abe M, Yano H, Tsukizaki R, Ozaki M, Nishiyama K, Saiki T, Watanabe S, Tsuda Y. The geomorphology, color, and thermal properties of Ryugu: Implications for parent-body processes. Science 2019; 364:252. [PMID: 30890587 DOI: 10.1126/science.aaw0422] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 03/12/2019] [Indexed: 11/02/2022]
Abstract
The near-Earth carbonaceous asteroid 162173 Ryugu is thought to have been produced from a parent body that contained water ice and organic molecules. The Hayabusa2 spacecraft has obtained global multicolor images of Ryugu. Geomorphological features present include a circum-equatorial ridge, east-west dichotomy, high boulder abundances across the entire surface, and impact craters. Age estimates from the craters indicate a resurfacing age of [Formula: see text] years for the top 1-meter layer. Ryugu is among the darkest known bodies in the Solar System. The high abundance and spectral properties of boulders are consistent with moderately dehydrated materials, analogous to thermally metamorphosed meteorites found on Earth. The general uniformity in color across Ryugu's surface supports partial dehydration due to internal heating of the asteroid's parent body.
Collapse
Affiliation(s)
- S Sugita
- The University of Tokyo, Tokyo 113-0033, Japan. .,Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - R Honda
- Kochi University, Kochi 780-8520, Japan
| | - T Morota
- Nagoya University, Nagoya 464-8601, Japan
| | - S Kameda
- Rikkyo University, Tokyo 171-8501, Japan
| | - H Sawada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - E Tatsumi
- The University of Tokyo, Tokyo 113-0033, Japan
| | - M Yamada
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - C Honda
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Yokota
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Kochi University, Kochi 780-8520, Japan
| | - T Kouyama
- National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064 Japan
| | - N Sakatani
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Ogawa
- Kobe University, Kobe 657-8501, Japan
| | - H Suzuki
- Meiji University, Kawasaki 214-8571, Japan
| | - T Okada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,The University of Tokyo, Tokyo 113-0033, Japan
| | - N Namiki
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - S Tanaka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - Y Iijima
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Yoshioka
- The University of Tokyo, Tokyo 113-0033, Japan
| | - M Hayakawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Cho
- The University of Tokyo, Tokyo 113-0033, Japan
| | - M Matsuoka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N Hirata
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - N Hirata
- Kobe University, Kobe 657-8501, Japan
| | - H Miyamoto
- The University of Tokyo, Tokyo 113-0033, Japan
| | - D Domingue
- Planetary Science Institute, Tucson, AZ 85719, USA
| | | | - T Nakamura
- Tohoku University, Sendai 980-8578, Japan
| | - T Hiroi
- Brown University, Providence, RI 02912, USA
| | - T Michikami
- Kindai University, Higashi-Hiroshima 739-2116, Japan
| | - P Michel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre National de le Recherche Scientifique (CNRS), Laboratoire Lagrange, 06304 Nice, France
| | - R-L Ballouz
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,University of Arizona, Tucson, AZ 85705, USA
| | - O S Barnouin
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - C M Ernst
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - S E Schröder
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - H Kikuchi
- The University of Tokyo, Tokyo 113-0033, Japan
| | - R Hemmi
- The University of Tokyo, Tokyo 113-0033, Japan
| | - G Komatsu
- International Research School of Planetary Sciences, Università d'Annunzio, 65127 Pescara, Italy.,Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - T Fukuhara
- Rikkyo University, Tokyo 171-8501, Japan
| | - M Taguchi
- Rikkyo University, Tokyo 171-8501, Japan
| | - T Arai
- Ashikaga University, Ashikaga 326-8558, Japan
| | - H Senshu
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - H Demura
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Ogawa
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Shimaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Sekiguchi
- Hokkaido University of Education, Asahikawa 070-8621, Japan
| | - T G Müller
- Max-Planck-Institut für Extraterrestrische Physik, 85748 Garching, Germany
| | - A Hagermann
- University of Stirling, FK9 4LA, Scotland, UK
| | - T Mizuno
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Noda
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - K Matsumoto
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - R Yamada
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Ishihara
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Ikeda
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - H Araki
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - K Yamamoto
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Abe
- Nihon University, Funabashi 274-8501, Japan
| | - F Yoshida
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - A Higuchi
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Sasaki
- Osaka University, Toyonaka 560-0043, Japan
| | - S Oshigami
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Tsuruta
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - K Asari
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Tazawa
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - M Shizugami
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - J Kimura
- Osaka University, Toyonaka 560-0043, Japan
| | - T Otsubo
- Hitotsubashi University, Tokyo 186-8601, Japan
| | - H Yabuta
- Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - S Hasegawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Ishiguro
- Seoul National University, Seoul 08826, Korea
| | - S Tachibana
- The University of Tokyo, Tokyo 113-0033, Japan
| | - E Palmer
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - R Gaskell
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - L Le Corre
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - R Jaumann
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - K Otto
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - N Schmitz
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - P A Abell
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - M A Barucci
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique (LESIA)-Observatoire de Paris, Paris Sciences et Lettres (PSL), Centre National de le Recherche Scientifique (CNRS), Sorbonne Université, Université Paris-Diderot, 92195 Meudon Principal Cedex, France
| | - M E Zolensky
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - F Vilas
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - F Thuillet
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre National de le Recherche Scientifique (CNRS), Laboratoire Lagrange, 06304 Nice, France
| | - C Sugimoto
- The University of Tokyo, Tokyo 113-0033, Japan
| | - N Takaki
- The University of Tokyo, Tokyo 113-0033, Japan
| | - Y Suzuki
- The University of Tokyo, Tokyo 113-0033, Japan
| | | | - M Okada
- The University of Tokyo, Tokyo 113-0033, Japan
| | - K Nagata
- National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064 Japan
| | - M Fujimoto
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Yoshikawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - Y Yamamoto
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - K Shirai
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - R Noguchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N Ogawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - F Terui
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Kikuchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Yamaguchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Oki
- The University of Tokyo, Tokyo 113-0033, Japan
| | - Y Takao
- The University of Tokyo, Tokyo 113-0033, Japan
| | - H Takeuchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - G Ono
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - Y Mimasu
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Yoshikawa
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - T Takahashi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Takei
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - A Fujii
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - C Hirose
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - S Nakazawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Hosoda
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - O Mori
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Shimada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Soldini
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Iwata
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - M Abe
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - H Yano
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - R Tsukizaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Ozaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - K Nishiyama
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Saiki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Watanabe
- Nagoya University, Nagoya 464-8601, Japan.,Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Tsuda
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| |
Collapse
|
28
|
Honma S, Kouno K, Takasaka S, Mitazaki S, Abe S, Kikuchi H, Oshima Y, Yoshida M. Effect of brefelamide on proliferation of 1321N1 human astrocytoma cells induced by glial cell line-derived neurotrophic factor. Pharmazie 2018; 73:22-28. [PMID: 29441947 DOI: 10.1691/ph.2018.7786] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Malignant gliomas are highly resistant to chemotherapy and radiation and more effective options for treatment are urgently needed. We reported previously that the aromatic amide brefelamide, which is isolated from methanolic extracts of the cellular slime molds Dictyostelium giganteum and D. brefeldianum, hinders cellular proliferation in a glioma model utilizing 1321N1 human astrocytoma cells. Herein, we examined the mechanisms underlying the inhibition of 1321N1 cell proliferation by brefelamide. Glial cell line-derived neurotrophic factor (GDNF) was found to enhance the rate of proliferation of serum-free cultured 1321N1 cells, but did not affect proliferation in PC12 cells. Brefelamide pretreatment inhibited GDNF-induced cell proliferation and expression of rearranged during transfection (RET). GDNF enhanced the phosphorylation of extracellular signal-regulated kinase (ERK), AKT, and c-jun-N-terminal kinase (JNK); however, brefelamide pretreatment inhibited these effects. Brefelamide also reduced the expression of GDNF mRNA and GDNF secretion. Together, the findings from this study indicate that brefelamide inhibits the proliferation of 1321N1 cell via several mechanisms including reduced GDNF receptor expression and GDNF secretion, and reduced phosphorylation of ERK, AKT, and JNK.
Collapse
|
29
|
Yoshino Y, Yuan B, Okusumi S, Aoyama R, Murota R, Kikuchi H, Takagi N, Toyoda H. Enhanced cytotoxic effects of arsenite in combination with anthocyanidin compound, delphinidin, against a human leukemia cell line, HL-60. Chem Biol Interact 2018; 294:9-17. [PMID: 30125548 DOI: 10.1016/j.cbi.2018.08.008] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Revised: 08/06/2018] [Accepted: 08/15/2018] [Indexed: 01/23/2023]
Abstract
Among five major anthocyanin compounds, delphinidin exhibited the most potent and selective cytocidal effect against HL-60, a trivalent arsenic (As(III))-resistant cell line. Co-treatment with delphinidin and As(III) resulted in the reduction of IC50 value for As(III) from 11.2 to 1.5 μM, which was considered as clinically achieved concentrations of As(III). The combination treatment strongly preferred to selectively enhance the cytotoxicity of As(III) against HL-60 cells rather than human peripheral blood mononuclear cells. The induction of apoptosis as evidenced by the increase of sub-G1 cells, DNA fragmentation, annexin V-positive cells and the activation of caspase-8, -9 and -3 was observed in HL-60 cells co-treated with As(III) and delphinidin. Similar to the activation pattern of caspases, a substantial decrease in the expression level of Bid along with the loss of mitochondrial membrane potential was also observed. These results suggested that the combination treatment triggered a convergence of the intrinsic and extrinsic pathways of apoptosis via the activation of caspase-8 and cleaved Bid. Delphinidin itself significantly decreased the intracellular GSH ([i]GSH) and nuclear factor-κB (NF-κB) binding activity, and further returned As(III)-triggered increment of [i]GSH and enhancement of NF-κB binding activity to control level. Additionally, buthionine sulfoximine, a GSH depletor; JSH-23, a NF-κB inhibitor, also mimicked the capacity of delphinidin to significantly induce the reduction of [i]GSH along with the potentiation of As(III) cytotoxicity in HL-60 cells. These observations suggested that delphinidin-induced sensitization of HL-60 cells to As(III) was caused by the reduction of [i]GSH, which was probably associated with the inhibitory effect of delphinidin on NF-κB binding activity. These findings further suggest that delphinidin-induced sensitization of HL-60 cells to As(III) may lead to dose reduction of As(III) in clinical application, and ultimately contribute to minimizing its side effects.
Collapse
Affiliation(s)
- Yuta Yoshino
- Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| | - Bo Yuan
- Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan; Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
| | - Saki Okusumi
- Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| | - Reiji Aoyama
- Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| | - Ryo Murota
- Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| | - Hidetomo Kikuchi
- Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| | - Norio Takagi
- Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| | - Hiroo Toyoda
- Department of Clinical Molecular Genetics, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan
| |
Collapse
|
30
|
Kimura Y, Yanagida T, Tsukui D, Asako K, Kikuchi H, Kono H. Decreased inflammasome activation in healthy subjects treated with benzbromarone. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Fujimaru T, Mori T, Sekine A, Mandai S, Chiga M, Kikuchi H, Ando F, Mori Y, Nomura N, Iimori S, Naito S, Okado T, Rai T, Hoshino J, Ubara Y, Uchida S, Sohara E. Kidney enlargement and multiple liver cyst formation implicate mutations in PKD1/2 in adult sporadic polycystic kidney disease. Clin Genet 2018. [PMID: 29520754 DOI: 10.1111/cge.13249] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Distinguishing autosomal-dominant polycystic kidney disease (ADPKD) from other inherited renal cystic diseases in patients with adult polycystic kidney disease and no family history is critical for correct treatment and appropriate genetic counseling. However, for patients with no family history, there are no definitive imaging findings that provide an unequivocal ADPKD diagnosis. We analyzed 53 adult polycystic kidney disease patients with no family history. Comprehensive genetic testing was performed using capture-based next-generation sequencing for 69 genes currently known to cause hereditary renal cystic diseases including ADPKD. Through our analysis, 32 patients had PKD1 or PKD2 mutations. Additionally, 3 patients with disease-causing mutations in NPHP4, PKHD1, and OFD1 were diagnosed with an inherited renal cystic disease other than ADPKD. In patients with PKD1 or PKD2 mutations, the prevalence of polycystic liver disease, defined as more than 20 liver cysts, was significantly higher (71.9% vs 33.3%, P = .006), total kidney volume was significantly increased (median, 1580.7 mL vs 791.0 mL, P = .027) and mean arterial pressure was significantly higher (median, 98 mm Hg vs 91 mm Hg, P = .012). The genetic screening approach and clinical features described here are potentially beneficial for optimal management of adult sporadic polycystic kidney disease patients.
Collapse
Affiliation(s)
- T Fujimaru
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - T Mori
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - A Sekine
- Nephrology Center, Toranomon Hospital, Tokyo, Japan
| | - S Mandai
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - M Chiga
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - H Kikuchi
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - F Ando
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Y Mori
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - N Nomura
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Iimori
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Naito
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - T Okado
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - T Rai
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - J Hoshino
- Nephrology Center, Toranomon Hospital, Tokyo, Japan.,Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
| | - Y Ubara
- Nephrology Center, Toranomon Hospital, Tokyo, Japan.,Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
| | - S Uchida
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - E Sohara
- Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
32
|
Yoshiuchi K, Sone M, Ishikawa T, Kikuchi H, Kumano H, Watsuji T, Natelson B, Yamamoto Y, Struzik Z. “Mobile Nurse” Platform for Ubiquitous Medicine. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1625391] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Objectives
: We introduce “Mobile Nurse" (MN) - an emerging platform for the practice of ubiquitous medicine.
Methods
: By implementing in a dynamic setting of daily life the patient care traditionally provided by the clinical nurses on duty, MN aims at integral data collection and shortening the response time to the patient. MN is also capable of intelligent interaction with the patient and is able to learn from the patient's behavior and disease sign evaluation for improved personalized treatment.
Results
: In this paper, we outline the most essential concepts around the hardware, software and methodological designs of MN. We provide an example of the implementation, and elaborate on the possible future impact on medical practice and biomedical science research.
Conclusions
: The main innovation of MN, setting it apart from current tele-medicine systems, is the ability to integrate the patient's signs and symptoms on site, providing medical professionals with powerfultools to elucidate disease mechanisms, to make proper diagnoses and to prescribe treatment.
Collapse
|
33
|
Nose K, Fujioka S, Yoshida R, Hayashi Y, Kitano K, Maruyama S, Kikuchi H, Tsuboi Y. A potential therapeutic option for postural deformities in Parkinson disease. Parkinsonism Relat Disord 2018. [DOI: 10.1016/j.parkreldis.2017.11.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Kikuchi H, Narita Y, Abe M, Odachi K, Kitano K, Harada Y, Fukagawa C, Nakai M, Tsuboyama Y. Nationwide survey of respite admission for incurable neurodegenerative diseases in japan. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Hirohata S, Kikuchi H, Sawada T, Kuwana M, Kirino Y, Takeno M, Ishigatsubo Y. Influences of timing of introduction of infliximab on the outcome of patients with chronic progressive neuro-Behcet's disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Kikuchi H, Hamauchi A, Sako K, Mizobuchi M, Abe T, Nihira A, Matsuda M. Agrammatism in progressive non-fluent aphasia of Japanese: Advantage of syntactic processing test of aphasia. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Inami T, Shigeta Y, Kataoka M, Fukushi K, Takeuchi K, Kikuchi H, Yoshino H, Satoh T. P2603Efficacy of ptpa for long-term outcome in chronic thromboembolic pulmonary hypertension. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Kikuchi H, Inami T, Kataoka M, Fukushi K, Takeuchi K, Shigeta Y, Yoshino H, Satoh T. P2599Efficacy of pulmonary hypertension-targeted drugs for chronic thromboembolic pulmonary hypertension after percutaneous transluminal pulmonary angioplasty. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Inami T, Kataoka M, Fukushi K, Takeuchi K, Kikuchi H, Shigeta Y, Yoshino H, Satoh T. P2608Efficacy of percutaneous transluminal pulmonary angioplasty for chronic pulmonary thromboembolism without pulmonary hypertension. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Wajima JT, Yamamoto H, Kikuchi H, Ohnishi T, Kobayashi S. Experimental Studies of Microparameters of Clusters of Seven Nuclear Superheat Reactor Fuel Rods. NUCL SCI ENG 2017. [DOI: 10.13182/nse68-a18004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. T. Wajima
- Ozenji Division, Central Research Laboratory, Hitachi, Ltd., Ozenji, Kawasaki, Kanagawa-Pref., Japan
| | - H. Yamamoto
- Ozenji Division, Central Research Laboratory, Hitachi, Ltd., Ozenji, Kawasaki, Kanagawa-Pref., Japan
| | - H. Kikuchi
- Ozenji Division, Central Research Laboratory, Hitachi, Ltd., Ozenji, Kawasaki, Kanagawa-Pref., Japan
| | - T. Ohnishi
- Ozenji Division, Central Research Laboratory, Hitachi, Ltd., Ozenji, Kawasaki, Kanagawa-Pref., Japan
| | - S. Kobayashi
- Ozenji Division, Central Research Laboratory, Hitachi, Ltd., Ozenji, Kawasaki, Kanagawa-Pref., Japan
| |
Collapse
|
41
|
Kikuchi H, Kogure S, Arai R, Saino K, Ohkubo A, Tsuda T, Sunaga K. Rosehip inhibits xanthine oxidase activity and reduces serum urate levels in a mouse model of hyperuricemia. Biomed Rep 2017; 6:539-544. [PMID: 28529735 PMCID: PMC5431748 DOI: 10.3892/br.2017.888] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 03/23/2017] [Indexed: 01/27/2023] Open
Abstract
Rosehip, the fruit of Rosa canina L., has traditionally been used to treat urate metabolism disorders; however, its effects on such disorders have not been characterized in detail. Therefore, the present study investigated the effects of hot water, ethanol and ethyl acetate extracts of rosehip on xanthine oxidase (XO) activity in vitro. In addition, the serum urate lowering effects of the rosehip hot water extract in a mouse model of hyperuricemia (male ddY mice, which were intraperitoneally injected with potassium oxonate) were investigated. Furthermore, the influence of rosehip hot water extract on CYP3A4 activity, which is the most important drug-metabolizing enzyme from a herb-drug interaction perspective, was investigated. Rosehip extracts of hot water, ethanol and ethyl acetate inhibited XO activity [half maximal inhibitory concentration (IC50) values: 259.6±50.6, 242.5±46.2 and 1,462.8±544.2 µg/ml, respectively]. Furthermore, the administration of 1X rosehip hot water extract significantly reduced the levels of serum urate at 8 h, which was similar when compared with the administration of 1 mg/kg allopurinol. Rosehip hot water extract only marginally affected CYP3A4 activity (IC50 value, >1 mg/ml). These findings indicate that rosehip hot water extract may present as a functional food for individuals with a high urate level, and as a therapeutic reagent for hyperuricemic patients.
Collapse
Affiliation(s)
- Hidetomo Kikuchi
- Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan
| | - Satomi Kogure
- Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan
| | - Rie Arai
- Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan
| | - Kouki Saino
- Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan
| | - Atsuko Ohkubo
- Development Division, Ryusendo Co., Ltd., Toshimaku, Tokyo 171-0021, Japan
| | - Tadashi Tsuda
- Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan
| | - Katsuyoshi Sunaga
- Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan
| |
Collapse
|
42
|
Lall N, Kishore N, Bodiba D, More G, Tshikalange E, Kikuchi H, Oshima Y. Alkaloids from aerial parts of Annona senegalensis against Streptococcus mutans. Nat Prod Res 2016; 31:1944-1947. [DOI: 10.1080/14786419.2016.1263847] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- N. Lall
- Department of Plant and soil Sciences, Plant Sciences Complex, University of Pretoria, Pretoria, South Africa
| | - N. Kishore
- Department of Plant and soil Sciences, Plant Sciences Complex, University of Pretoria, Pretoria, South Africa
| | - D. Bodiba
- Department of Plant and soil Sciences, Plant Sciences Complex, University of Pretoria, Pretoria, South Africa
| | - G. More
- Department of Plant and soil Sciences, Plant Sciences Complex, University of Pretoria, Pretoria, South Africa
| | - E. Tshikalange
- Department of Plant and soil Sciences, Plant Sciences Complex, University of Pretoria, Pretoria, South Africa
| | - H. Kikuchi
- Department of Plant and soil Sciences, Plant Sciences Complex, University of Pretoria, Pretoria, South Africa
- Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai, Japan
| | - Y. Oshima
- Department of Plant and soil Sciences, Plant Sciences Complex, University of Pretoria, Pretoria, South Africa
- Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai, Japan
| |
Collapse
|
43
|
Kimura Y, Yanagida T, Onda A, Asako K, Kikuchi H, Kono H. Soluble uric acid promotes development of atherosclerosis lesions via enhancement of innate inflammation in mice. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Kikuchi H, Tanaka S, Nakagiri Y, Yamane T, Fujiwara S, Katsuhisa K, Tan A, Matsuo O. Hypofibrinolytic Activity after Total Joint Replacement. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/153857449202600110] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Tissue-type plasminogen activator (t-PA), tissue-type plasminogen activator inhibitor (t-PAI), and other factors (platelets, fibrinogen, fibrinogen degrada tion products, antithrombin-III, plasminogen, and α2-plasmin inhibitor [α2-PI]) related to the fibrinolytic system were studied in 21 patients undergoing total joint replacement. Seventeen of the 21 patients revealed an impaired fibrinolytic activity from the first to seventh postoperative day and a subsequent return to the preopera tive level by the fourteenth postoperative day. There were accompanying increases in the level of α2-PI and in the t-PAI/t-PA ratio, and there was decrease in plas minogen level. Such hypofibrinolytic states may be related to a higher incidence of postoperative thrombosis in total joint replacement patients.
Collapse
Affiliation(s)
- H. Kikuchi
- Department of Orthopaedic Surgery, Kinki University School of Medicine
| | - S. Tanaka
- Department of Orthopaedic Surgery, Kinki University School of Medicine
| | - Y. Nakagiri
- Department of Orthopaedic Surgery, Kinki University School of Medicine
| | - T. Yamane
- Department of Orthopaedic Surgery, Kinki University School of Medicine
| | - S. Fujiwara
- Department of Orthopaedic Surgery, Kinki University School of Medicine
| | - K. Katsuhisa
- Department of Orthopaedic Surgery, Kinki University School of Medicine
| | - A. Tan
- Department of Orthopaedic Surgery, Kinki University School of Medicine
| | - O. Matsuo
- Department of Physiology, Kinki University School of Medicine, Osakasayama, Japan
| |
Collapse
|
45
|
Abstract
There have been some studies on the relationship between tension-type headache (TTH) and physical activity. However, most previous studies were not prospective and assessed physical activity by questionnaire. Therefore, this study was aimed to investigate the relationship between TTH intensity and physical activity prospectively utilizing computerized ecological momentary assessment and actigraphy Thirty-one TTH patients wore watch-type computers equipped with actigraphy inside for 1 week to record momentary headache intensity and physical activity. Multilevel modelling was used to investigate the effect of headache intensity on the simultaneous and subsequent activity level. There were significant negative associations between headache intensity and the simultaneous and subsequent activity level, and activity level was significantly reduced at headache exacerbations. These results provide objective and quantitative evidence suggesting that TTH negatively affects physical activity.
Collapse
Affiliation(s)
- H Kikuchi
- Department of Psychosomatic Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
| | | | | | | | | |
Collapse
|
46
|
Abe G, Arinuma Y, Sakuma Y, Kikuchi H, Hirohata S. THU0326 Brain MRI in Patients with Acute Confusional State of Diffuse Psychiatric/neuropsychological Syndromes in Systemic Lupus Erythematosus. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Ishigatsubo Y, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondou K, Hibi T. THU0589 Infliximab Therapy for Neuro-, Vascular, and Intestinal Behçet's Disease: Efficacy, Safety, and Pharmacokinetics in A Multicenter Prospective Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
48
|
Kamiya M, Soen S, Kikuchi H, Okada N. AB1029 Costs of Biological Agents and Patterns of Biological Therapy in Routine Treatment for Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, Ishigatsubo Y. Long-term outcome of chronic progressive neurological manifestations in behcet's disease. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Kikuchi H, Hirohata S. Cognitive impairment in chronic progressive neuro-behçet’s disease: comparative study of brainstem and hippocampus region using brain MRI. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|